DURECT Corporation to Announce Second Quarter 2020 Financial Results and Provide Business Update on August 03
DURECT Corporation (Nasdaq: DRRX) will announce its second quarter 2020 financial results on August 3, 2020, at 4:30 PM ET. The call will detail developments regarding their lead candidate DUR-928, aimed at treating alcoholic hepatitis and COVID-19-related liver injuries. DURECT emphasizes the innovation of its drug delivery technologies, including POSIMIR® for post-surgery pain relief. Forward-looking statements highlight potential risks, including clinical trial delays and the possibility of FDA non-approval for its products.
- DUR-928 is in Phase 2 development for alcoholic hepatitis and COVID-19 liver injuries.
- POSIMIR® offers a novel analgesic approach for post-surgery pain relief.
- Potential delays in DUR-928 trials due to changes in standard care.
- Risks of not replicating previous trial results for DUR-928.
- FDA approval for POSIMIR is uncertain.
CUPERTINO, Calif., July 28, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter 2020 financial results and host a conference call after the market close on Monday, August 3, 2020.
Monday, August 3 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time | |
Toll Free: | 877-407-0784 |
International: | 201-689-8560 |
Conference ID: | 13706541 |
Webcast: | |
About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DURECT's lead candidate, DUR-928 is an endogenous sulfated oxysterol and an epigenetic regulator. It represents a new class of therapeutics with a unique mechanism of action. DUR-928 epigenetically modulates the expression of multiple clusters of master genes that are involved in many important cell signaling pathways, through which it stabilizes mitochondria, reduces lipotoxicity, regulates inflammatory or stress responses, and promotes cell survival. This drug candidate is currently in Phase 2 development for the treatment of alcoholic hepatitis (AH) and the treatment of COVID-19 patients with acute liver or kidney injury as well as Phase 1 development for the treatment of nonalcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine extended-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. For more information about DURECT, please visit www.durect.com.
DURECT Forward-Looking Statement
The statements in this press release regarding clinical development plans for DUR-928, including the potential use of DUR-928 to treat COVID-19 patients with liver or kidney injury, the potential use of DUR-928 to treat acute organ injuries, such as AH, and chronic liver diseases, such as NASH, and the potential use of POSIMIR to provide pain relief after surgery are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of DUR-928 in COVID-19 patients is delayed or stopped because of changes to the standard of care, the availability of alternative therapies, required protocol changes or lack of available patients, the risk that future clinical trials of DUR-928 are not started when anticipated, take longer to conduct than anticipated, do not replicate the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of DUR-928 in a statistically significant manner, the risk that the FDA will not approve POSIMIR, the risk that additional time and resources may be required for development, testing and regulatory approval of DUR-928 or the Company's other product candidates, potential adverse effects arising from the testing or use of our drug candidates, our potential failure to maintain our collaborative agreements with third parties and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on May 11, 2020 under the heading "Risk Factors."
NOTE: POSIMIR® and SABER® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 and POSIMIR are investigational drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.
View original content:http://www.prnewswire.com/news-releases/durect-corporation-to-announce-second-quarter-2020-financial-results-and-provide-business-update-on-august-03-301100868.html
SOURCE DURECT Corporation
FAQ
When will DURECT Corporation release its Q2 2020 financial results?
What are the clinical developments for DUR-928?
What is the significance of POSIMIR for DURECT Corporation?
What risks are associated with DURECT's product candidates?
